RT Journal Article
T1 Endoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study)
A1 Valdés, Sergio
A1 Olveira-Fuster, Gabriel María
A1 Sánchez-Torralvo, Francisco José
A1 Vázquez-Pedreño, Luis
A1 Gonzalo-Marín, Montserrat
A1 Tapia Guerrero, María José
A1 Lima-Rubio, Fuensanta
A1 García-Fuentes, Eduardo
A1 García, Pilar
A1 Moreno-Ruiz, Francisco Javier
A1 Rodríguez-Cañete, Alberto
K1 Obesidad
AB Intragastric injection of botulinum toxin A (BT-A) has been shown to beeffective for weight loss up to six months after administration, according to previous studies. Ourobjective was to determine, in patients on bariatric surgery waiting lists, the effect of BT-A on weightloss in the pre- and postoperative period and to analyse if there are different responses based onBody Mass Index (BMI). Methods: We performed a follow-up analysis of the IntraTox study, whichincluded 46 patients on bariatric surgery waiting lists in a single-centre, randomised, double-blind,placebo-controlled clinical trial. The treatment group received intragastric BT-A, whereas the controlgroup received physiological saline solution. The one-time procedure was performed at the timeof diagnostic endoscopy 7–8 months before surgery. Weight loss was evaluated at admission andafter 4 and 12 weeks from the bariatric surgery. Our analysis was stratified by BMI at randomisation.Results: weight loss percentage on the day of surgery, with respect to the initial visit, was −4.5 ± 3.9%for the control group vs. −7.6 ± 4.2%, for the treatment group (p = 0.013). Weight loss percentagetended to remain greater in the treatment group one month after the intervention (−12.7 ± 4.7% vs.−15.2 ± 4.6%, p = 0.07) and become similar three months after (−21.6 ± 4.7% vs. −21.6 ± 4.6%). Afterstratifying by BMI, only patients with BMI over 50 kg/m2 allocated to the treatment group obtaineda greater weight loss at the end of the trial, the day of surgery, and one month after, compared withthe placebo group (−4.9 ± 4.9%, −10.8 ± 5.3% and −17.1 ± 3.8% vs. −0.1 ± 2.6%, −4.3 ± 3.2%and −12.8 ± 4.1%, respectively (p < 0.05). Conclusions: intragastric injection of BT-A is effective toachieve significant weight loss, especially in extreme obesity. Its use before bariatric surgery enhancesperioperative weight loss.
PB IOAP-MPDI
YR 2022
FD 2022-04-11
LK https://hdl.handle.net/10630/24309
UL https://hdl.handle.net/10630/24309
LA spa
NO Sánchez-Torralvo FJ, Vázquez-Pedreño L, Gonzalo-Marín M, Tapia MJ, Lima F, García-Fuentes E, García P, Moreno-Ruiz J, Rodríguez-Cañete A, Valdés S, Olveira G. Endoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study). Journal of Clinical Medicine. 2022; 11(8):2126. https://doi.org/10.3390/jcm11082126
NO Merz Pharma (Frankfurt am Main, Germany) collaborated with a non-restricted grant.The study was co-funded by the Sociedad Andaluza de Endocrinología, Diabetes y Nutrición (SAEDYN) and the Sociedad Andaluza de Nutrición, Clínica y Dietética (SANCYD). This research wassupported by the Plataforma Española de Investigación Clínica y Ensayos Clínicos, SCReN (SpanishClinical Research Network), funded by ISCIII-Subdirección General de Evaluación y Fomento de laInvestigación, through the projects PT13/0002/0020 and PT17/0020, integrated in the Plan Estatal deI+D+I 2013-2016 and co-funded by the European Regional Development Fund (ERDF). Partial funding for open access charge: Universidad de Málaga
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026